MAHA Commission Report on Children’s Health Takes Aim at Ultra-Processed Foods and Medication Practices, Among Other Targets

May 23, 2025

Reading Time : 2 min

Yesterday, the White House’s Make America Healthy Again (MAHA) Commission, led by the Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. released its inaugural health report titled, Make Our Children Healthy Again, delivering one of the first widely anticipated deliverables from the MAHA Commission Executive Order issued earlier this year and noted in our prior alert. The 72-page assessment examines the rising rates of childhood chronic disease in the country—including obesity, heart disease and diabetes—and explores potential contributing factors. Specifically, the report identifies and focuses on four potential drivers:

  • Ultra-Processed Foods (UPFs). The report links the increased consumption of UPFs high in added sugars, chemical additives and saturated fats to poor health outcomes in children. The report also states that government programs such as the Supplemental Nutrition Assistance Program (SNAP) and the School Breakfast Program and National School Lunch Program (NSLP) have contributed to the overconsumption of UPFs.
  • Exposure to Environmental Chemicals. The Commission identifies a need for continued studies to better understand the impact of exposure to various substances including per- and polyfluoroalkyl substances (PFAS), fluoride, electromagnetic radiation and phthalates.
  • Lack of Physical Activity and Chronic Stress: The report discusses the pervasive use of screens, increasing sedentary lifestyles and childhood mental health decline as areas of concern.
  • Overmedicalization: The report states that “excessive medical intervention” including an overuse of prescription drugs and vaccines may exacerbate chronic childhood illness. The report calls for inquiry into the impacts of vaccine injury, links between vaccines and chronic disease, and conflicts of interest in the development of the vaccine schedule.

Next Steps

The report outlines ten proposed research initiatives, setting the stage for follow-on actions and potential policy changes as the MAHA Commission’s work moves forward. The report identifies ten areas for further research, including recommending several research initiatives to guide efforts to combat childhood chronic disease including evaluating self-affirmed GRAS (Generally Recognized as Safe) food ingredients, assessing the impact of whole-food, reduced-carb and low-UPF diets in children, and applying AI and machine learning to federal health and nutrition datasets for early detection of harmful exposures and childhood chronic disease trends. The report also proposes focusing on research replication, post-marketing surveillance, leveraging real world data to study childhood chronic diseases, drug safety studies, alternative testing models, and mapping gene–environment interactions affecting childhood disease risk. The MAHA Commission plans to release a strategy in August 2025. However, it is likely that the Commission will provide updates on some of these research items before August, and agencies such as FDA and NIH will likely start announcing initiatives based on this report.

Share This Insight

Previous Entries

Eye on FDA

November 5, 2025

Last week, FDA released draft guidance titled “Scientific Considerations in Demonstrating Biosimilarity to a Reference Product: Updated Recommendations for Assessing the Need for Comparative Efficacy Studies.” This draft guidance reflects an evolution in FDA’s approach to determining whether a comparative clinical study with efficacy endpoints (a comparative efficacy study or CES) is necessary to support a demonstration of biosimilarity. Specifically, the agency notes that a comparative analytical assessment (CAA) is generally more sensitive when it comes to detecting differences between products than a CES.

...

Read More

Eye on FDA

October 27, 2025

On October 23, 2025, FDA released its final guidance regarding Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments. The guidance is the third guidance in a four-part series of FDA guidance focused on patient-focused drug development (PFDD) that describe how stakeholders, such as patients, caregivers, researchers, medical product developers and others can submit patient experience data and other relevant information that can be used for medical product development and regulatory decision making.

...

Read More

Eye on FDA

October 23, 2025

On October 16, 2025, the Food and Drug Administration (FDA) unveiled the first group of nine voucher recipients under the Commissioner’s National Priority Voucher (CNPV) pilot program, a program announced by the agency earlier this year that provides a path for accelerated drug review for companies supporting national interests as determined by the Commissioner. The identified areas of priority by the agency include meeting large unmet medical needs, bolstering domestic manufacturing and increasing the affordability of medicines for American patients. As previously noted, the new program, which is not defined in statute or regulations, aims to significantly speed up FDA’s standard 10-12 month review timeline to just 1-2 months after filing an application for a drug or biologic. The agency has touted the  benefit of recipients of the vouchers receiving enhanced access with FDA review staff and a “team-based review” model.

...

Read More

Eye on FDA

October 9, 2025

On September 30, 2025, the Food and Drug Administration (FDA) published a Request for Public Comment to obtain feedback from interested parties on current approaches to measuring and evaluating the performance of AI-enabled medical devices. Specifically, FDA is seeking feedback on best practices, methodologies and approaches for measuring and evaluating real-world performance of AI-enabled medical devices from the public.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.